LRRK2 pathobiology in Parkinson's disease – virtual inclusion. (22nd February 2016)

• Record Type: Journal Article
• Authors: Martin, Ian; Kim, Jungwoo Wren; Dawson, Valina L.; Dawson, Ted M.
• Is Part Of: Journal of neurochemistry. Volume 139(2016)Supplement 1
• Page Start: 75
• Page End: 76
• Publication Date: 2016-02-22
• Subjects: Neurochemistry -- Periodicals; 616.8042
• DOI: 10.1111/jnc.13549
• Languages: English
• ISSNs: 0022-3042

Abstract

Abstract: A common cause of Parkinson disease are missense mutations in the leucine‐rich repeat kinase 2 (LRRK2) catalytic Roc‐COR domain, leading to a decrease in GTPase activity; and its kinase domain, leading to an increase in kinase activity and subsequent LRRK2 toxicity. Targeting LRRK2 with selective, brain‐permeable kinase inhibitors is a promising approach to reduce toxicity, and thus is a major goal of clinical development. Understanding the specific signaling cascades triggered by LRRK2 mutations will be key to this aim. This article is part of a special issue on Parkinson disease . Abstract : This article is part of a special issue on Parkinson disease .